Scancell Holdings Plc Scancell to Present at Two Conferences

TIDMSCLP

Scancell Holdings Plc

12 November 2018

12 November 2018

Scancell Holdings Plc

("Scancell" or the "Company")

Scancell to present at the LSX InvEUR$tival Showcase and

5(th) BioCentury-BayHelix China Healthcare Summit

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, will be presenting at the LSX (formerly Biotech and Money) InvEUR$tival Showcase, being held on 13 November at The Waldorf Hilton, Aldwych, London, WC2B 4DD.

Dr Cliff Holloway, Chief Executive Officer of Scancell, will be presenting an overview of the Company and will be available to take questions following the event. The presentation will take place at 10:45am and may be viewed live through the following web link: https://www.lsxleaders.com/investival-showcase/stream-01

In addition, Dr Richard Goodfellow, Non-Executive Director and former CEO of Scancell will be presenting at the 5(th) BioCentury-BayHelix China Healthcare Summit in Shanghai. The summit is being held on 13(th) - 14(th) November at the Jing An Shangri-La in Shanghai, China.

Both presentations will be available through the following link: https://www.scancell.co.uk/investors/company-docs

For Further Information:

 
 Scancell Holdings Plc 
 Dr John Chiplin, Chairman             [phone] 
 Dr Cliff Holloway, CEO 
 
 Panmure Gordon (UK) Limited 
  (Nominated Adviser and Corporate 
  broker) 
 Freddy Crossley/Emma Earl             [phone] 
 
 FTI Consulting 
  Mo Noonan/Simon Conway               [phone] 
 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.

ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

-- SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

-- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.

Moditope(R) represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4+ T cells which overcome the immune suppression induced by tumours. allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope(R) alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

-- Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.

For further details, please see our website: www.scancell.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAUAAORWBAAAUA

(END) Dow Jones Newswires

November 12, 2018 02:00 ET (07:00 GMT)